HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN

This article was originally published in The Rose Sheet

Executive Summary

FDA requests comments on development of fiscal year 2002 (beginning Oct. 1) program priorities in July 18 Federal Register notice. Comments are due Sept. 17. Among CFSAN's completed 2001 "A" list goals is initiation of activities to ensure cosmetics, dietary supplements and foods containing bovine materials from BSE-identified countries are restricted from entering U.S., center says in July 10 report card highlighting 53 "A" list accomplishments through June 15. Guidance outlining cosmetic office's plan to send warning letters to manufacturers based on insufficient data findings by Cosmetic Ingredient Review board is expected by late summer (1"The Rose Sheet" June 11, In Brief). Other initiatives left on cosmetic office's "A" list include DEA risk assessment, labeling guidance for alpha hydroxy acid-containing products (2"The Rose Sheet" Jan. 15, p. 10)

You may also be interested in...



Insufficent data labeling

Guidance outlining FDA's decision to send warning letters to cosmetic manufacturers based on Cosmetic Ingredient Review Expert Panel findings will be published in Federal Register notice by "late summer," FDA Office of Cosmetics and Colors Acting Director Adele Dennis says during panel meeting June 4-5 in Washington, D.C. Warning letters likely will be issued to manufacturers using ingredients determined by CIR to have insufficient data to establish safety and will require manufacturers to place warning labels on products. Action, which was placed on FDA's Cosmetics & Colors "A" lists of priorities, is expected to encourage companies to submit more data to CIR to prevent insufficient data rulings. Regulation is "first step in the process of determining whether or not the safety of cosmetic products is being compromised" by businesses, she says. Agency has authority to impose warning statements on cosmetics that lack safety data under Section 740.10 of FD&C Act (1"The Rose Sheet" May 29, 2000, p. 3)

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel